{"publication_id":"ad6bd204-1859-4516-b412-8f3a7f40f350","screening":{"identified":22,"screened":22,"excluded":0,"included":22,"included_or_retained":22,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"22 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The conclusion is that senescence cancer effects remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.","The curated corpus lacks randomized controlled trials (RCTs) directly testing senescence-targeting interventions against cancer outcomes, creating a critical gap in establishing causal efficacy. The absence of long-term mortality or recurrence trials in adults with or without cancer limits the ability to translate biomarker associations into clinically actionable endpoints, leaving the boundary conditions for senescence modulation undefined. This limitation is compounded by the inclusion of only one study (Moskalevska 2026) examining longevity outcomes, which reports a 20% survival increase in males but lacks replication in broader populations, further constraining generalizability.","The corpus exhibits a pronounced mechanistic-to-clinical translation gap, where senescence-related claims are supported by preclinical or indirect human data without corresponding clinical validation. For example, Lin 2021 and Fang 2023 link senescence patterns to immunotherapeutic responses and cancer outcomes, respectively, but these associations are not grounded in trials demonstrating that targeting senescence (e.g., via senolytics) improves clinical endpoints. Similarly, Moskalevska 2026 reports healthspan and survival benefits in animal models, yet these findings are not replicated in human RCTs, leaving the clinical feasibility of senescence-targeting strategies uncertain. This disconnect is exacerbated by the inclusion of mechanistic reviews (e.g., Sobolewski 2026) that highlight histological markers without demonstrating their actionability in patient care, further widening the chasm between bench and bedside.","For senescence cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 13 curated reference papers, the evidence base for Senescence shows a context-dependent profile. Null findings dominate: contextual other, muscle function. The Senescence anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}